Standout Papers

FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of... 2021 2026 2022 2024226
  1. FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma (2021)
    Uğur Şahin, Ö. Türeci et al. Annals of Oncology

Citation Impact

55 standout
Sub-graph 1 of 18

Citing Papers

Exosome circATP8A1 induces macrophage M2 polarization by regulating the miR-1-3p/STAT6 axis to promote gastric cancer progression
2024 Standout
Stomach microbiota in gastric cancer development and clinical implications
2024 Standout
7 intermediate papers

Works of Andriy Rusyn being referenced

FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma
2021 Standout
Final results of the FAST study, an international, multicenter, randomized, phase II trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without the anti-CLDN18.2 antibody IMAB362 as first-line therapy in patients with advanced CLDN18.2+ gastric and gastroesophageal junction (GEJ) adenocarcinoma
2016
and 3 more

Author Peers

Author Oncology PRM RNMI Immunology Last Decade Papers Cites
Andriy Rusyn 277 202 96 107 16 463
Sinan Atmaca 48 72 15 1 31 312
Teresa Torns 30 240
L. A. Hazell 2 14 8 40 17 550
Bianca Lima Ferreira 15 45 136 12 400
Melissa G. Booth 9 7 419

All Works

Loading papers...

Rankless by CCL
2026